Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): An open-label pilot study

被引：0
|
作者：
Quigley, Bonnie L. [1 ,2 ]
Can, Adem T. [1 ]
Dutton, Megan [1 ]
Gallay, Cyrana C. [1 ]
Forsyth, Grace [1 ]
Jones, Monique [1 ]
Randall, Fiona [1 ]
Wilson, Trish [1 ]
Lagopoulos, Jim [3 ]
Hermens, Daniel F. [1 ]
机构：
[1] Univ Sunshine Coast, Natl PTSD Res Ctr, Thompson Inst, Birtinya, Qld 4575, Australia
[2] Univ Sunshine Coast, Ctr Bioinnovat, Sippy Downs, Qld 4556, Australia
[3] Thompson Brain & Mind Healthcare, Maroochydore, Qld 4558, Australia
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2025年 / 93卷
关键词：
Ketamine; Low dose oral ketamine; Post-traumatic stress disorder; PTSD;
D O I：
10.1016/j.euroneuro.2025.01.003
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [1] Olanzapine treatment for post-traumatic stress disorder: an open-label study
    Petty, F
    Brannan, S
    Casada, J
    Davis, LL
    Gajewski, V
    Kramer, GL
    Stone, RC
    Teten, AL
    Worchel, J
    Young, KA
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (06) : 331 - 337
  • [2] Treatment of post-traumatic stress disorder with phenytoin: An open label pilot study
    Bremner, JD
    Mletzko, T
    Welter, S
    Reed, L
    Williams, C
    Heim, C
    Nemeroff, C
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S91 - S91
  • [3] Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
    Adem T. Can
    Daniel F. Hermens
    Megan Dutton
    Cyrana C. Gallay
    Emma Jensen
    Monique Jones
    Jennifer Scherman
    Denise A. Beaudequin
    Cian Yang
    Paul E. Schwenn
    Jim Lagopoulos
    Translational Psychiatry, 11
  • [4] Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
    Can, Adem T.
    Hermens, Daniel F.
    Dutton, Megan
    Gallay, Cyrana C.
    Jensen, Emma
    Jones, Monique
    Scherman, Jennifer
    Beaudequin, Denise A.
    Yang, Cian
    Schwenn, Paul E.
    Lagopoulos, Jim
    TRANSLATIONAL PSYCHIATRY, 2021, 11 (01)
  • [5] Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder
    Pablo Roitman
    Raphael Mechoulam
    Rena Cooper-Kazaz
    Arieh Shalev
    Clinical Drug Investigation, 2014, 34 : 587 - 591
  • [6] Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder
    Roitman, Pablo
    Mechoulam, Raphael
    Cooper-Kazaz, Rena
    Shalev, Arieh
    CLINICAL DRUG INVESTIGATION, 2014, 34 (08) : 587 - 591
  • [7] Clinical effects of anodal tDCS and identifying response markers in post-traumatic stress disorder (PTSD): An open-label study
    Rezaei, Mehdi
    Bagheri, Mohammad Mahdi Shariat
    BEHAVIOURAL BRAIN RESEARCH, 2024, 458
  • [8] Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study
    Ahearn, EP
    Mussey, M
    Johnson, C
    Krohn, A
    Krahn, D
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (01) : 29 - 33
  • [9] Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study
    Lubin, G
    Weizman, A
    Shmushkevitz, M
    Valevski, A
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2002, 17 (04) : 181 - 185
  • [10] Risperidone treatment for post-traumatic stress disorder (PTSD)
    Petty, F
    Padala, PR
    Monnahan, M
    Ramaswamy, S
    Madison, JK
    Marcil, WA
    Perry, PL
    Wilson, DR
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 171S - 171S
12345